Introduction
============

Recent evidence has suggested a potential association between Alzheimer's disease (AD) and chronic glaucoma. Glaucoma is a group of optic neuropathies that are characterized by progressive neurodegeneration of retinal ganglion cells and their axons, resulting in structural changes of the optic nerve and visual field defects.[@b1-opth-8-2095] Elevated intraocular pressure is a major risk factor of glaucoma,[@b2-opth-8-2095] and open-angle glaucoma is its most prevalent form worldwide.[@b3-opth-8-2095] Dementia is also a group of neurodegenerative disorders that occurs in the elderly and leads to impaired cognition. AD is the most common type of dementia[@b4-opth-8-2095] and is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles consisted of hyperphosphorylated tau protein.[@b5-opth-8-2095]

Therefore, it has been suggested that AD and glaucoma are indirectly associated via common pathophysiological mechanisms or risk factors.[@b6-opth-8-2095]--[@b12-opth-8-2095] Neuro-inflammation may be an important mechanism for the development of both AD and glaucoma.[@b6-opth-8-2095] The complement component 1q is upregulated in AD, as well as in mouse and monkey glaucoma models.[@b7-opth-8-2095],[@b8-opth-8-2095] Elevated tumor necrosis factor-α concentrations contribute to the neurodegeneration process in AD and glaucoma.[@b9-opth-8-2095],[@b10-opth-8-2095] In addition, some studies have shown similar levels of both amyloid β~1--42~ and tau protein in the cerebrospinal fluid of AD patients and in the vitreous fluid of glaucoma patients.[@b11-opth-8-2095],[@b12-opth-8-2095]

However, it is unclear if the AD and glaucoma association is causal. Some epidemiological studies have reported a higher risk of glaucoma in patients with AD or a higher risk of AD in patients with glaucoma,[@b13-opth-8-2095]--[@b18-opth-8-2095] whereas other studies reported null or even inverse associations.[@b19-opth-8-2095]--[@b22-opth-8-2095] The reasons underlying these heterogeneous findings need to be investigated, but no formal evaluation of this literature has been published. Therefore, we performed a systematic review to describe and critically appraise the findings of the AD and chronic glaucoma literature.

Materials and methods
=====================

Study identification
--------------------

We searched systematically in PubMed from December 1964 through September 2013 to identify observational studies that investigated the association between AD or dementia with chronic glaucoma using the following algorithm: "(glaucoma or primary open-angle glaucoma or pseudoexfoliation glaucoma) and (dementia or Alzheimer's disease or vascular dementia)". No language restrictions were imposed. We excluded articles that did not have glaucoma or dementia as the outcome, that had no human or original data, and that did not have a control group. We also excluded screening and case-report studies. Our search identified 239 studies potentially relevant for abstract review ([Figure 1](#f1-opth-8-2095){ref-type="fig"}). There were 100 studies claimed for full-text review based on information in the abstracts. Of these, ten articles were established as pertinent.[@b13-opth-8-2095]--[@b22-opth-8-2095] Abstract and full-text review was conducted independently by two investigators (AGT and KKT) and discrepancies were resolved by consensus. The methodological quality of the included studies was assessed independently by AGT and KKT using the Newcastle-Ottawa scale, which accords a maximum of nine points to each study, with five or less points indicating a high risk of bias.[@b23-opth-8-2095] Data on each study, including location, population, design, number of cases and controls, method of assessment of glaucoma and AD, mean age, percentage of males, type of statistical analysis, relative risk (RR) and 95% confidence interval (CI), matching and adjustment factors were independently abstracted into a standardized form. We further systematically searched for relevant articles in EMBASE and the COCHRANE databases, but no further articles were deemed eligible.

Statistical analysis
--------------------

We abstracted the maximally adjusted RR estimates and 95% CIs for the association of AD or dementia and glaucoma. The eligible studies reported odds ratios, hazard ratios (HRs) or standardized incidence ratios, which were considered equivalent given that AD and glaucoma are relatively rare except in populations over 80 years.[@b24-opth-8-2095],[@b25-opth-8-2095] Some studies did not provide RR estimates in the publication, and we calculated matched or unmatched odds ratios from 2×2 tables.[@b13-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] Bayer et al published two small case-control studies in 2002 with insufficient information as to whether they used independent samples.[@b14-opth-8-2095],[@b15-opth-8-2095] Further information was requested from the authors but no details were supplied, and the samples were assumed independent for this meta-analysis.

The statistical synthesis was performed using the fixed effects method with each RR estimate weighted by the inverse of its variance. We did not conduct a random effects synthesis, because it tends to be overtly inflated in the presence of small study effects, as the small studies receive increased relative weight in random effects calculations.[@b26-opth-8-2095] We performed a meta-analysis for the association between AD and glaucoma (eight studies) and separately for dementia and glaucoma (nine studies), but the results were very heterogeneous and were therefore not reported in detail in the text or in tables and figures.

Subgroup analyses were also performed to investigate potential sources of heterogeneity. We repeated the fixed effects synthesis after omitting one study at a time. The association of dementia and glaucoma was assessed by study location (Europe, USA, Asia), design (cohort, record linkage, case-control), number of cases (≥100, \<100), use of matching or adjustment (for at least one factor, crude) and mean age of the study population at recruitment (≥75, \<75 years). To test whether the summary estimates differed between strata of the latter characteristics, we conducted meta-regression analyses.

Statistical heterogeneity (variability) across studies was evaluated using the Cochran Q test and the *I*^2^ statistic[@b27-opth-8-2095],[@b28-opth-8-2095] with its corresponding 95% CIs.[@b29-opth-8-2095] An *I*^2^ value of 0% implies lack of heterogeneity, whereas values of 25%, 50% and 75% imply low, medium, and high heterogeneity respectively. Publication bias (bias against the publication of negative results or publication of those results after considerable delay) was quantified from the visual inspection of a funnel plot,[@b30-opth-8-2095] from the Begg rank correlation method[@b31-opth-8-2095] and the Egger's regression asymmetry test (publication bias considered present if *P*≤0.10).[@b30-opth-8-2095] A nonparametric "trim and fill" method that accounts for publication bias was also applied.[@b32-opth-8-2095] All statistical analyses were performed with STATA software version 12 (StataCorp LP, College station, TX, USA), and all tests were two-sided.

Results
=======

Ten studies were selected according to our inclusion criteria ([Figure 1](#f1-opth-8-2095){ref-type="fig"}, [Tables 1](#t1-opth-8-2095){ref-type="table"} and [2](#t2-opth-8-2095){ref-type="table"}). Six studies were conducted in Europe,[@b14-opth-8-2095],[@b15-opth-8-2095],[@b17-opth-8-2095],[@b19-opth-8-2095],[@b20-opth-8-2095],[@b22-opth-8-2095] two in the United States[@b13-opth-8-2095],[@b21-opth-8-2095] and two in Asia.[@b16-opth-8-2095],[@b18-opth-8-2095] Five reports were case-control studies,[@b13-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] of which two used prevalent cases,[@b14-opth-8-2095],[@b15-opth-8-2095] two were record-linkage studies[@b20-opth-8-2095],[@b22-opth-8-2095] and another three were cohort studies,[@b17-opth-8-2095],[@b19-opth-8-2095],[@b21-opth-8-2095] of which one was a retrospective cohort.[@b21-opth-8-2095] All studies used patients with open angle glaucoma, a form of glaucoma that has been hypothesized to have neurodegenerative elements. The number of cases with glaucoma in these studies ranged between 21 and 63,325. Participants had a mean age at recruitment that ranged from 64 to 83 years. Most case-control studies had less than 350 total participants[@b14-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] except for one study using death certificates that had more than 20,000 participants but very few exposed cases,[@b13-opth-8-2095] and all observed large positive and strongly significant RRs for the association between AD or dementia and glaucoma. In contrast, the large retrospective cohort study with 63,325 cases of glaucoma observed a statistically significant inverse association,[@b21-opth-8-2095] whereas other prospective cohort and record-linkage studies reported mixed results.[@b17-opth-8-2095],[@b19-opth-8-2095],[@b20-opth-8-2095],[@b22-opth-8-2095] One study was further excluded from the meta-analysis, because it did not identify any case with AD, and thus calculated a zero RR.[@b22-opth-8-2095]

The median Newcastle-Ottawa quality score was 4 with an interquartile range (IQR) from 4 to 7 ([Tables S1](#SD1-opth-8-2095){ref-type="supplementary-material"} and [S2](#SD2-opth-8-2095){ref-type="supplementary-material"}). The five case-control studies[@b13-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] scored poorly in the quality scale (median, 4; IQR, 2--4) because most studies did not independently validate the case definition; they did not use population-based controls, and did not control for important potential confounders. The four cohort and record-linkage studies[@b17-opth-8-2095],[@b19-opth-8-2095]--[@b21-opth-8-2095] had a median quality score of 7 (IQR, 5.5--7), and all but one[@b20-opth-8-2095] had scores of 7.

Compared to non-demented participants, patients with AD (eight studies; RR, 0.92; 95% CI, 0.89--0.94; *I*^2^, 89%; *P*~heterogeneity~, \<0.001) or with dementia (nine studies; RR, 0.94; 95% CI, 0.92--0.96; *I*^2^, 89.4%; *P*~heterogeneity~, \<0.001) had a statistically significant decreased risk of glaucoma, respectively ([Figures 2](#f2-opth-8-2095){ref-type="fig"} and [3](#f3-opth-8-2095){ref-type="fig"}). The study results were very heterogeneous and tended to follow the finding of the largest study in our sample.[@b21-opth-8-2095] After excluding the Ou et al[@b21-opth-8-2095] study, the findings changed to a statistically significant positive association, but they were still very heterogeneous.

Funnel plots and statistical tests (AD and glaucoma: Egger's *P*~heterogeneity~, 0.01; Dementia and glaucoma: Egger's *P*~heterogeneity~, \<0.001) provided evidence for substantial publication bias, as there were several very small studies with large and positive RRs.[@b14-opth-8-2095]--[@b18-opth-8-2095] When we attempted to correct for publication bias using the non-parametric trim and fill method, the results of the meta-analysis remained identical, as adding several small studies with strong inverse associations to the funnel plot did not leverage the results of the large Ou et al study. In meta-analyses performed by study location, design, number of cases, use of adjustments for confounders and mean age, dementia was associated with a lower risk of glaucoma in the subgroups where the Ou et al study belonged (studies in USA, cohorts, number of cases ≥100, adjusted results, and mean age ≥75 years), whereas the summary results were significantly positive in all other subgroups ([Table S3](#SD3-opth-8-2095){ref-type="supplementary-material"}).

Discussion
==========

In this systematic review, we critically appraised ten studies for the association between AD or dementia and chronic glaucoma. The findings of the ten studies were extremely heterogeneous and ranged from large positive RRs identified in small and poorly-conducted case-control studies to weak inverse associations or null estimates observed in some cohort and record-linkage studies. The summary estimate was identical to the result of the large Ou et al retrospective cohort study, which reported an inverse association between AD and glaucoma but this study used medical claims to infer about diagnosis of dementia and glaucoma and it may be afflicted by underdiagnosis bias.

It is unclear pathophysiologically why there should be an inverse association between AD and glaucoma. Although the literature has not provided potential mechanistic clues for an inverse association, many researchers have suggested mechanisms explaining a positive association between the two diseases. It has been shown that patients with AD exhibit a cerebrospinal fluid stasis due to decreased secretion and increased resistance to cerebrospinal fluid outflow,[@b33-opth-8-2095]--[@b36-opth-8-2095] resulting in reduced clearance of the toxic molecules in the subarachnoid space of the optic nerve and a low cerebrospinal fluid pressure, which may lead to an abnormal high trans-lamina cribrosa pressure difference and to a larger cup-to-disc ratio followed by glaucomatous damage.[@b37-opth-8-2095]--[@b40-opth-8-2095] However, other studies have suggested that even though an abnormal high trans-lamina cribrosa pressure difference is created, there is no observable alteration in the lamina cribrosa resulting in no optic disc cupping,[@b41-opth-8-2095] which does not support an association between AD and glaucoma. Several factors should be considered for the interpretation of our findings. AD and chronic glaucoma are both age-related neurodegenerative diseases that may very well co-exist in the elderly due to common risk factors or pathophysiological mechanisms. However, to infer a direct and causal association between them, prospective designs are warranted where chronic glaucoma is evaluated many years after the diagnosis of AD (or vice versa) in participants who are free of glaucoma (or any early signs of it) at the start of the study. Sensitivity analyses where the first 2--5 years of follow-up are discarded may assist in identifying a potential causal effect.

However, half of the studies that were included in this systematic review had a case-control design that precludes a valid assessment of the association between AD and glaucoma, as both diseases were evaluated cross-sectionally at recruitment.[@b13-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] The study sample also included one record-linkage[@b20-opth-8-2095] and three cohort studies.[@b17-opth-8-2095],[@b19-opth-8-2095],[@b21-opth-8-2095] The retrospective cohort by Ou et al used Medicare data to identify 63,325 participants with glaucoma and 63,325 participants without glaucoma who had no AD or other dementia at recruitment, and were followed up for 14 years.[@b21-opth-8-2095] This was by far the largest study in our sample, and found a statistically significant inverse association between glaucoma and AD (HR, 0.91; 95% CI, 0.88--0.93). The use of administrative data in this study may lead to misclassification of the diagnoses of glaucoma and/or dementia and to potential underdiagnosis bias. Patients with cognitive decline are perhaps less likely to undergo formal ophthalmologic testing and this could cause the non-glaucoma group to contain a larger proportion of individuals who are subsequently diagnosed with dementia. The French cohort by Helmer et al studied 812 volunteers and identified 41 cases of dementia in 3 years of total follow-up.[@b17-opth-8-2095] They observed a strong statistically significant positive association between dementia and glaucoma (HR, 3.90; 95% CI, 1.50--10.4). Although this study was prospective and excluded demented participants at recruitment, its short follow-up led to a small number of incident dementia cases who most likely had brain pathology at least at a mild level at baseline. The third cohort study was conducted in Sweden among 1,123 city residents; it identified 174 new cases of AD in a maximum follow-up of 25 years and reported a non-significant HR of 1.09 (95% CI, 0.69--1.74) between AD and chronic glaucoma.[@b19-opth-8-2095]

High heterogeneity was ubiquitous in all of our analyses. Heterogeneity may be introduced because of the methodologic or demographic differences among studies. However, we were unable to identify the exact sources of heterogeneity in our systematic review, because the summary results were always driven by the large Ou et al study, even though we performed subgroup and meta-regression analyses on several factors. However, even when we reran the meta-analysis after excluding the Ou et al study, the results remained heterogeneous. Therefore, we decided not to report in detail the summary RRs.

Meta-analyses of observational studies are also vulnerable to residual confounding inherent in the original studies. The Ou et al and Helmer et al studies both adjusted for a range of confounders that included age, sex, race, education, family history of glaucoma, and comorbidities.[@b17-opth-8-2095],[@b21-opth-8-2095] The case-control studies adjusted only for age and/or sex, whereas some studies did report frequency matching for a wider set of confounders;[@b14-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095] however, RRs were not reported in these studies and had to be calculated crudely from 2×2 tables, which may explain at least partially why the authors observed strong positive associations, as some comorbidities and the black race are positively associated with both AD and glaucoma and could cause the overestimation of the unadjusted results.

Conclusion
==========

In summary, the association of AD and chronic glaucoma is heterogeneous in the literature and most studies are small and inadequately designed. Large and high-quality prospective studies with long follow-ups are needed to clarify the existence, magnitude, and natural history of this potential association.

Supplementary materials
=======================

###### 

Newcastle-Ottawa scale for the quality assessment of five case-control studies on dementia and glaucoma risk

  Quality assessment criteria                        Acceptable                                                               Chandra et al[@b13-opth-8-2095]   Bayer et al[@b14-opth-8-2095]   Bayer et al[@b15-opth-8-2095]   Tamura et al[@b16-opth-8-2095]   Cumurcu et al[@b18-opth-8-2095]
  -------------------------------------------------- ------------------------------------------------------------------------ --------------------------------- ------------------------------- ------------------------------- -------------------------------- ---------------------------------
  Selection                                                                                                                                                                                                                                                      
   Is the case definition adequate?                  Yes, with independent validation                                         --                                --                              --                              --                               --
   Representativeness of cases?                      Consecutive or obviously representative cases                            √                                 √                               √                               --                               --
   Selection of controls?                            Community controls                                                       √                                 --                              --                              --                               --
   Definition of controls?                           No history of AD/glaucoma[\*](#tfn13-opth-8-2095){ref-type="table-fn"}   --                                √                               √                               √                                --
  Comparability                                                                                                                                                                                                                                                  
   Study controls for age and sex?                   Yes[\#](#tfn14-opth-8-2095){ref-type="table-fn"}                         √                                 --                              --                              --                               --
   Study controls for additional factors?            Race, comorbidities[‡](#tfn15-opth-8-2095){ref-type="table-fn"}          --                                --                              --                              --                               --
  Exposure                                                                                                                                                                                                                                                       
   Ascertainment of exposure?                        Secure record or structured interview blinded to case/control status     --                                √                               √                               --                               --
   Same method of ascertainment of cases/controls?   Yes                                                                      √                                 √                               √                               √                                √
   Non-response rate?                                Same for both groups                                                     √                                 --                              --                              --                               --

**Notes:**

Depending on whether AD or glaucoma was the outcome in each case-control study

some case-control studies[@b15-opth-8-2095]--[@b17-opth-8-2095],[@b19-opth-8-2095] did report frequency matching for age and sex, but these studies did not report relative risks in the text and they had to be calculated crudely from 2×2 tables

some case-control studies[@b15-opth-8-2095],[@b16-opth-8-2095] did report frequency matching for comorbidities, but these studies did not report relative risks in the text and they had to be calculated crudely from 2×2 tables.

**Abbreviation:** AD, Alzheimer's disease.

###### 

Newcastle-Ottawa scale for the quality assessment of four cohort and record-linkage studies on dementia and glaucoma risk

  Quality assessment criteria                                                  Acceptable                                                                    Kessing et al[\*](#tfn17-opth-8-2095){ref-type="table-fn"},[@b20-opth-8-2095]   Ou et al[\#](#tfn18-opth-8-2095){ref-type="table-fn"},[@b21-opth-8-2095]   Helmer et al[\#](#tfn18-opth-8-2095){ref-type="table-fn"},[@b17-opth-8-2095]   Ekstrom and Kilander[\#](#tfn18-opth-8-2095){ref-type="table-fn"},[@b19-opth-8-2095]
  ---------------------------------------------------------------------------- ----------------------------------------------------------------------------- ------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------------------
  Selection                                                                                                                                                                                                                                                                                                                                                                                            
   Representativeness of exposed cohort?                                       Representative of average adult in community                                  √                                                                               √                                                                          --                                                                             --
   Selection of non-exposed cohort?                                            Drawn from same community as exposed cohort                                   √                                                                               √                                                                          √                                                                              √
   Ascertainment of exposure?                                                  Secure records or structured interview                                        --                                                                              --                                                                         √                                                                              √
   Demonstration that outcome of interest was not present at start of study?                                                                                 --                                                                              √                                                                          √                                                                              √
  Comparability                                                                                                                                                                                                                                                                                                                                                                                        
   Study controls for age and sex?                                             Yes                                                                           √                                                                               √                                                                          √                                                                              √
   Study controls for additional risk factors?                                 Race, comorbidities                                                           --                                                                              √                                                                          √                                                                              --
  Outcome                                                                                                                                                                                                                                                                                                                                                                                              
   Assessment of outcome?                                                      Independent blind assessment or record linkage                                --                                                                              --                                                                         √                                                                              √
   Was follow-up long enough for outcome to occur?                             Follow-up \>5 years                                                           √                                                                               √                                                                          --                                                                             √
   Adequacy of follow-up of cohorts?                                           Complete follow-up or subjects lost to follow-up unlikely to introduce bias   --                                                                              √                                                                          √                                                                              √

**Notes:**

Record-linkage study

cohort study.

###### 

Summary fixed-effects relative risks (RR) and 95% confidence intervals (CI) for the association of dementia in general and glaucoma in subgroups

  Outcome measures           No of studies                                                                                      Summary RR (95% CI)   *P*~heterogeneity~[\*](#tfn19-opth-8-2095){ref-type="table-fn"}
  -------------------------- -------------------------------------------------------------------------------------------------- --------------------- -----------------------------------------------------------------
  Study location                                                                                                                                      
   Europe                    5[@b14-opth-8-2095],[@b15-opth-8-2095],[@b17-opth-8-2095],[@b19-opth-8-2095],[@b20-opth-8-2095]    1.14 (1.03--1.27)     \<0.01
   USA                       2[@b13-opth-8-2095],[@b21-opth-8-2095]                                                             0.93 (0.91--0.95)     0.03
   Asia                      2[@b16-opth-8-2095],[@b18-opth-8-2095]                                                             3.61 (2.11--6.20)     0.38
  Study design                                                                                                                                        
   Cohort                    3[@b17-opth-8-2095],[@b19-opth-8-2095],[@b21-opth-8-2095]                                          0.93 (0.91--0.95)     0.01
   Record-linkage            1[@b20-opth-8-2095]                                                                                1.08 (0.97--1.20)     \<0.01
   Case-control              5[@b13-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095]                                         3.94 (2.71--5.72)     0.57
  Number of cases                                                                                                                                     
   \<100                     3[@b14-opth-8-2095],[@b17-opth-8-2095],[@b18-opth-8-2095]                                          4.60 (2.64--8.02)     0.90
   ≥100                      6[@b13-opth-8-2095],[@b15-opth-8-2095],[@b16-opth-8-2095],[@b19-opth-8-2095]--[@b21-opth-8-2095]   0.94 (0.92--0.96)     \<0.01
  Matching or adjustment                                                                                                                              
   For at least one factor   5[@b13-opth-8-2095],[@b17-opth-8-2095],[@b19-opth-8-2095]--[@b21-opth-8-2095]                      0.94 (0.92--0.96)     \<0.01
   Crude                     4[@b14-opth-8-2095]--[@b16-opth-8-2095],[@b18-opth-8-2095]                                         4.29 (2.84--6.48)     0.59
  Mean age                                                                                                                                            
   \<75 years                5[@b14-opth-8-2095],[@b15-opth-8-2095],[@b18-opth-8-2095]--[@b20-opth-8-2095]                      1.14 (1.03--1.27)     \<0.01
   ≥75 years                 4[@b13-opth-8-2095],[@b16-opth-8-2095],[@b17-opth-8-2095],[@b21-opth-8-2095]                       0.93 (0.91--0.95)     \<0.01

**Note:**

Evaluated in each subgroup using the Cochran Q test.

**Author contributions**

All authors (AGT, KKT, S-HP, GK) contributed to the conception and design of the study. AGT and KKT acquired the data for the systematic review, performed the statistical analysis, and wrote the paper. S-HP and GK contributed critically to the revisions of the paper and had valuable input to the clinical interpretation of the discussion. All authors contributed toward data analysis, drafting and revising the paper and agree to be accountable for all aspects of the work.
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![Flow diagram of the study selection process.\
**Notes:** We further systematically searched for relevant articles in EMBASE and the COCHRANE databases, but no further articles were deemed eligible.](opth-8-2095Fig1){#f1-opth-8-2095}

![Study-specific relative risks and 95% confidence intervals (CI) for the association of Alzheimer's disease (AD) and chronic glaucoma.\
**Notes:** We decided not to report the statistical synthesis of the results from the eight eligible studies because of the substantial heterogeneity (*I*^2^, 89%; *P*~heterogeneity~, \<0.001).](opth-8-2095Fig2){#f2-opth-8-2095}

![Study-specific relative risks and 95% confidence intervals (CI) for the association of dementia in general and chronic glaucoma.\
**Notes:** We decided not to report the statistical synthesis of the results from the nine eligible studies because of the substantial heterogeneity (*I*^2^, 89%; *P*~heterogeneity~, \<0.001).](opth-8-2095Fig3){#f3-opth-8-2095}

###### 

Study characteristics of the ten eligible studies on dementia and glaucoma risk

  Study                                                                              Location/population          Design                                                            Cases/controls                                       Exposure/outcome   Assessment of glaucoma               Assessment of AD/dementia
  ---------------------------------------------------------------------------------- ---------------------------- ----------------------------------------------------------------- ---------------------------------------------------- ------------------ ------------------------------------ ---------------------------
  Chandra et al, 1986[@b13-opth-8-2095]                                              USA/general population       Case-control                                                      7,195/14,390                                         OAG/AD             Death certificate                    Death certificate
  Bayer et al, 2002[@b14-opth-8-2095],[\#](#tfn2-opth-8-2095){ref-type="table-fn"}   Germany/nursing homes        Prevalent case-control                                            49/186                                               OAG/AD             Glaucomatous VFD, CDR ≥0.8           NR
  Bayer et al, 2002[@b15-opth-8-2095],[\#](#tfn2-opth-8-2095){ref-type="table-fn"}   Germany/nursing homes        Prevalent case-control                                            112/116                                              OAG/AD             Glaucomatous VFD, CDR ≥0.8           NINCDS-ADRDA
  Tamura et al, 2006[@b16-opth-8-2095]                                               Japan/hospitals              Case-control                                                      172/176                                              OAG/AD             ACAW, VCDR \>0.7, VCDRD \>0.2        NINCDS-ADRDA
  Kessing et al, 2007[@b20-opth-8-2095]                                              Denmark/general population   Record-linkage                                                    11,721[\*](#tfn1-opth-8-2095){ref-type="table-fn"}   AD/OAG             ICD-8, ICD-10                        ICD-8, ICD-10
  Bach-Holm et al, 2011[@b22-opth-8-2095]                                            Denmark/hospital             Record-linkage                                                    69[\*](#tfn1-opth-8-2095){ref-type="table-fn"}       OAG/AD             Glaucomatous VFD, IOP ≤24 mmHg       ICD-8, ICD-10
  Ou et al, 2012[@b21-opth-8-2095]                                                   USA/medicare beneficiaries   Retrospective cohort[‡](#tfn3-opth-8-2095){ref-type="table-fn"}   63,325/63,325                                        OAG/AD             ICD-9                                ICD-9
  Cumurcu et al, 2013[@b18-opth-8-2095]                                              Turkey/hospital              Case-control                                                      21/67                                                AD/OAG             IOP ≥21mmHg, glaucomatous ODD/VFD    DSM-IV (2000)
  Helmer et al, 2013[@b17-opth-8-2095]                                               France/study volunteers      CohortI[II](#tfn4-opth-8-2095){ref-type="table-fn"}               41/771                                               AD/OAG             VCDR ≥0.65, MRDR ≤0.1, VCDRD \>0.2   DSM-IV (1994)
  Ekstrom and Kilander, 2013[@b19-opth-8-2095]                                       Sweden/study volunteers      Cohort[¶](#tfn5-opth-8-2095){ref-type="table-fn"}                 174/949                                              AD/OAG             IOP, VFD                             NINCDS-ADRDA

**Notes:**

Patients with glaucoma compared to glaucoma prevalence or incidence rates from the general population of each country

it is not clear if these studies used independent samples

14 years of follow-up

3 years of follow-up

over 25 years of follow-up.

**Abbreviations:** ACAW, anterior chamber's angle width; AD, Alzheimer's disease; CDR, cup-to-disc ratio; DSM-IV, *Diagnostic and Statistical Manual of Mental Disorders*, fourth edition; ICD, International Statistical Classification of Diseases and related health problems; IOP, intraocular pressure; MRDR, minimal rim to disc ratio; NINCDS-ADRDA, National Institute of Neurological and Communicative Disorders and Stroke -- Alzheimer's Disease and Related Disorders Association; NR, not reported; OAG, open-angle glaucoma; ODD, optic disc damage; VCDR, vertical cup-to-disc ratio; VCDRD, vertical cup-to-disc ratio difference; VFD, visual field defect.

###### 

Population characteristics of the ten eligible studies on dementia and glaucoma risk

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                          Matching criteria                                                                                   Mean age, years\   \% males\          Statistical analysis                                     RR (95% CI)\        RR (95% CI)\                RR (95% CI)\         Adjustment factors
                                                                                                                                                     (cases/controls)   (cases/controls)                                                            (AD and OAG)        (non-AD dementia and OAG)   (dementia and OAG)   
  ---------------------------------------------- --------------------------------------------------------------------------------------------------- ------------------ ------------------ -------------------------------------------------------- ------------------- --------------------------- -------------------- --------------------------------------------------------------------------------------
  Chandra et al, 1986[@b13-opth-8-2095]          Age, sex, race, year, and county of death[†](#tfn8-opth-8-2095){ref-type="table-fn"}                80.1/79.8          40.6/NR            Matched OR[\*](#tfn7-opth-8-2095){ref-type="table-fn"}   2.60 (1.06--6.43)   NR                          NR                   None

  Bayer et al, 2002[@b14-opth-8-2095]            Age, sex, fam hx of glaucoma, myopia, systemic disease[‡](#tfn9-opth-8-2095){ref-type="table-fn"}   72.9/68.4          38.8/43.5          Crude OR[\*](#tfn7-opth-8-2095){ref-type="table-fn"}     4.70 (1.95--11.4)   NR                          NR                   None

  Bayer et al, 2002[@b15-opth-8-2095]            Age, sex, fam hx of glaucoma, myopia, systemic disease[‡](#tfn9-opth-8-2095){ref-type="table-fn"}   71.8/68.2          33.9/34.5          Crude OR[\*](#tfn7-opth-8-2095){ref-type="table-fn"}     6.41 (2.56--16.1)   NR                          NR                   None

  Tamura et al, 2006[@b16-opth-8-2095]           Age, sex[‡](#tfn9-opth-8-2095){ref-type="table-fn"}                                                 80.9/81.9          20.3/23.9          Crude OR[\*](#tfn7-opth-8-2095){ref-type="table-fn"}     3.13 (1.67--5.85)   NR                          NR                   None

  Kessing et al, 2007[@b20-opth-8-2095]          None                                                                                                70.9               46.6               SIR                                                      0.76 (0.56--1.05)   0.95 (0.85--1.07)           1.08 (0.97--1.20)    Age, sex

  Bach-Holm et al, 2011[@b22-opth-8-2095]        None                                                                                                64.0               27.5               SIR                                                      0 (0--4.06)         0.20 (0.01--1.11)           NR                   Age, sex

  Ou et al, 2012[@b21-opth-8-2095]               Age, sex, race, CCI[II](#tfn10-opth-8-2095){ref-type="table-fn"}                                    78.5/78.5          36.0/34.0          HR                                                       0.91 (0.88--0.93)   NR                          0.93 (0.91--0.95)    Age, sex, race, CCI, ophthalmic diseases[¶](#tfn11-opth-8-2095){ref-type="table-fn"}

  Cumurcu et al, 2013[@b18-opth-8-2095]          Age, sex, education[‡](#tfn9-opth-8-2095){ref-type="table-fn"}                                      NR/70.9            NR/71.6            Crude OR[\*](#tfn7-opth-8-2095){ref-type="table-fn"}     5.44 (1.88--15.6)   NR                          NR                   None

  Helmer et al, 2013[@b17-opth-8-2095]           None                                                                                                83.2/79.5          21.9/36.1          OR                                                       NR                  NR                          3.90 (1.50--10.4)    Age, sex, education, fam hx of glaucoma, vascular diseases, *Apoe4*

  Ekstrom and Kilander, 2013[@b19-opth-8-2095]   None                                                                                                NR                 NR                 HR                                                       1.09 (0.69--1.74)   NR                          NR                   Age, sex
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

The point estimates and 95% confidence intervals of the relative risks were not reported in these publications, and were thus calculated from 2×2 tables. Crude odds ratios were calculated in four studies because frequency matching was performed.

Individual matching was used

frequency matching was most likely used

propensity score matching was used

macular degeneration, diabetic retinopathy, vitreous hemorrhage, cataract, pseudophakia/aphakia.

**Abbreviations:** AD, Alzheimer's disease; Apoe4, apolipoprotein e4; CCI, Charlson comorbidity index; CI, confidence internal; fam hx, family history; HR, hazard ratio; NR, not reported; OAG, open-angle glaucoma; OR, odds ratio; RR, relative risk; SIR, standardized incidence ratio.
